Citation styles don't seem to be passed to Word Conversion
The citation style for this book is set as:
But NO citations are getting tagged in the converted XML (see below).
Are these settings get passed to NCBI?
<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper
PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "BITS-book2.dtd">
<book-part-wrapper content-type="chapter" id="LM1246"><book-meta><book-id book-id-type="pmcid">cokotestword4</book-id><book-title-group><book-title>book title</book-title></book-title-group><publisher><publisher-name>publisher</publisher-name><publisher-loc>pub place</publisher-loc></publisher></book-meta><book-part book-part-type="chapter"><?word-to-xml processor="extyles"?><book-part-meta><title-group><title>Aflibercept</title></title-group><pub-history><date date-type="revised"><day>16</day><month>11</month><year>2020</year></date></pub-history><kwd-group><kwd>Aflibercept</kwd><kwd>Zaltrap</kwd><kwd>Eylea</kwd><kwd>VEGF Trap</kwd><kwd>VEGF Trap-Eye</kwd><kwd>VEGF Trap R1R2</kwd><kwd>VEGF Trap - regeneron</kwd><kwd>Aflibercept [USAN:INN]</kwd><kwd>UNII-15C2VL427D</kwd><kwd>HSDB 8258</kwd><kwd>AVE0005</kwd><kwd>Bay86-5321</kwd><kwd>Aflibercept iso-osmotic ophthalmic</kwd><kwd>15C2VL427D</kwd><kwd>Bay 86-5321</kwd><kwd>AVE 0005</kwd><kwd>862111-32-8</kwd></kwd-group></book-part-meta><body><p>CASRN: 862111-32-8</p><sec id="LM1246.Drug_Levels_and_Effects"><title>Drug Levels and Effects</title><sec id="LM1246.Summary_of_Use_during_Lactation"><title>Summary of Use during Lactation</title><p content-type="pubmed-excerpt">This record refers to the use of intravitreal aflibercept. Aflibercept inhibits vascular endothelial growth factor (VEGF). Aflibercept is a is a large protein molecule with a molecular weight of 115,000, absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract, so systemic effects in infants are not expected. The manufacturer estimates that after intravitreal administration of 2 mg, the mean maximum plasma concentration of free aflibercept is more than 100-fold lower than the concentration of aflibercept required to half-maximally bind systemic vascular endothelial growth factor. Since VEGF is present in human milk and is thought to help in maturation of the infant’s gastrointestinal tract, concern has been raised about the maternal use of VEGF inhibitors during breastfeeding.[1] Note that the typical alternative to breastmilk is infant formula, which contains no VEGF.</p></sec><sec id="LM1246.Drug_Levels"><title>Drug Levels</title><p><italic toggle="yes">Maternal Levels.</italic> A woman with diabetic macular edema was given intravitreal aflibercept 2 mg one week postpartum. She was not breastfeeding her infant. Milk samples were obtained before the injection and on days 1-4 after the injection. Aflibercept was detected only on day 4 in a concentration of 10.9 mcg/L.[2]</p><p><italic toggle="yes">Infant Levels.</italic> Relevant published information was not found as of the revision date.</p></sec><sec id="LM1246.Effects_in_Breastfed_Infants"><title>Effects in Breastfed Infants</title><p>Relevant published information was not found as of the revision date.</p></sec><sec id="LM1246.Effects_on_Lactation_and_Breastmi"><title>Effects on Lactation and Breastmilk</title><p>A woman with diabetic macular edema was given intravitreal aflibercept 2 mg one week postpartum. She was not breastfeeding her infant. Milk samples were obtained before the injection and on days 1-4 after the injection. VEGF levels were reduced from 10.6 mcg/L at baseline to 4.9 mcg/L on day 1, where it remained for the next 3 days.[2]</p></sec><sec id="LM1246.Alternate_Drugs_to_Consider"><title>Alternate Drugs to Consider</title><p>(Intravitreal) <related-object link-type="booklink" source-id="cokotestword4" document-id="LM825" document-type="book-part">Bevacizumab</related-object>, <related-object link-type="booklink" source-id="cokotestword4" document-id="LM1012" document-type="book-part">Ranibizumab</related-object></p></sec><sec id="LM1246.References"><title>References</title><ref-list><ref id="LM1246.REF.1"><label>1</label><element-citation publication-type="journal"><person-group><name name-style="western"><surname>Dalal</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Patel</surname><given-names>AL</given-names></name><name name-style="western"><surname>Carle</surname><given-names>M</given-names></name><etal/></person-group><article-title>Review of ophthalmic and breastfeeding medicine evidence: Real and theoretical risks of intravitreal Anti-VEGF administration in lactating women.</article-title><source>Retina</source><year>2020</year><volume>40</volume><fpage>2065</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">32796446</pub-id></element-citation></ref><!-- Q1 Reference 1 "Dalal, Patel, Carle, et al., 2020" is not cited in the text. Please add an in-text citation or delete the reference. --><ref id="LM1246.REF.2"><label>2</label><element-citation publication-type="journal"><person-group><name name-style="western"><surname>Juncal</surname><given-names>VR</given-names></name><name name-style="western"><surname>Paracha</surname><given-names>Q</given-names></name><name name-style="western"><surname>Bamakrid</surname><given-names>M</given-names></name><etal/></person-group><article-title>Ranibizumab and aflibercept levels in breast milk after intravitreal injection.</article-title><source>Ophthalmology</source><year>2020</year><volume>127</volume><fpage>278</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">31526521</pub-id></element-citation></ref><!-- Q2 Reference 2 "Juncal, Paracha, Bamakrid, et al., 2020" is not cited in the text. Please add an in-text citation or delete the reference. --></ref-list></sec></sec><sec id="LM1246.Substance_Identification"><title>Substance Identification</title><sec id="LM1246.Substance_Name"><title>Substance Name</title><p>Aflibercept</p></sec><sec id="LM1246.CAS_Registry_Number"><title>CAS Registry Number</title><p>862111-32-8</p></sec><sec id="LM1246.Drug_Class"><title>Drug Class</title><p>Breast Feeding</p><p>Lactation</p><p>Angiogenesis Inhibitors</p><p>Recombinant Fusion Proteins</p></sec></sec></body></book-part></book-part-wrapper>